Perspectivas del mercado y visión del analista:
La enfermedad de Alzheimer (EA) es un trastorno neurológico causado por la muerte progresiva de las neuronas. Los síntomas comienzan gradualmente y pueden provocar demencia. Aunque la afección no se puede curar por completo, existen medicamentos disponibles que pueden aliviar temporalmente los síntomas y ralentizar la progresión de la enfermedad. La alta prevalencia de la EA, particularmente en la población de edad avanzada, y las crecientes actividades de investigación y desarrollo en la industria farmacéutica para introducir diagnósticos y terapias para la enfermedad son los factores clave que impulsan el crecimiento del mercado de medicamentos para el Alzheimer. Sin embargo, los efectos secundarios de los medicamentos y el estricto entorno regulatorio obstaculizan el progreso del mercado. Además, se espera que el creciente interés en los tratamientos personalizados y los medicamentos de precisión para la EA genere nuevas tendencias en el mercado de medicamentos para el Alzheimer en los próximos años.
Impulsores de crecimiento y restricciones:
Los crecientes casos de EA y demencia relacionada impulsan el tamaño del mercado de medicamentos para el Alzheimer. La enfermedad de Alzheimer es la forma más común de demencia en todo el mundo y representa entre el 60% y el 70% de todos los casos. Es una enfermedad neurodegenerativa progresiva que empeora gradualmente con los años y es más común en la población que envejece. Según el informe de la Organización Mundial de la Salud (OMS) publicado en octubre de 2022, la población mundial de 60 años o más crecerá hasta los 1.400 millones en 2030 y alcanzará los 2.100 millones en 2050. Se prevé que esta creciente población geriátrica aumentará la carga de morbilidad, facilitando la demanda de tratamientos médicos relacionados en los próximos años.
Además, el aumento de la conciencia sobre la EA, la mejora de las tasas de diagnóstico y el aumento de las inversiones en el desarrollo de nuevos tratamientos son los factores que facilitan el crecimiento del mercado. Según un informe publicado por la Asociación de Alzheimer en 2021, la asociación invirtió 63 millones de dólares en 2020 para avanzar en la investigación sobre el Alzheimer y la demencia.
Sin embargo, los posibles efectos secundarios expresan implicaciones significativas para la progresión del mercado de medicamentos contra el Alzheimer. Los inhibidores de la acetilcolinesterasa (IECA) y los antagonistas del receptor NMDA son la clase de fármacos comúnmente recetados para el tratamiento de la EA. Aunque estos medicamentos se usan ampliamente y se consideran generalmente seguros cuando se usan según las indicaciones, varios efectos secundarios específicos y preocupaciones están asociados con su uso. Los efectos adversos más importantes asociados con los medicamentos para la EA son mareos, náuseas, diarrea y dolor abdominal en caso de sobredosis o cuando se usan de manera inapropiada. Esta es una preocupación importante y puede afectar la confianza del consumidor en el producto, lo que podría conducir a una disminución del uso. Según un artículo publicado en 2021 por ScienceDirect Journal, los estudios realizados para evaluar las reacciones adversas de los medicamentos utilizados en el tratamiento de la EA informaron eventos adversos cardíacos asociados con los AChEI y efectos secundarios gastrointestinales como estreñimiento, diarrea, vómitos y dolor abdominal asociados con Memantina. Por lo tanto, los efectos secundarios de estos medicamentos obstaculizan el mercado de medicamentos para el Alzheimer.
Perspectivas estratégicas
Segmentación y alcance del informe:
El “análisis del mercado de medicamentos para el Alzheimer” se ha llevado a cabo considerando los siguientes segmentos: clase de medicamento y canal de distribución.
Análisis segmentario:
Según la clase de fármaco, el mercado se segmenta en inhibidores de la colinesterasa, antagonistas del receptor NMDA, fármacos combinados y fármacos en fase de desarrollo. El segmento de inhibidores de la colinesterasa representó la mayor cuota de mercado de medicamentos para el Alzheimer en 2022. Se estima que el segmento de medicamentos en desarrollo registrará la CAGR más alta durante 2022-2030. El segmento de inhibidores de la colinesterasa se divide aún más en donepezilo, galantamina y rivastigmina. Los inhibidores de la colinesterasa son recetados por especialistas como psiquiatras o neurólogos para la EA en etapa temprana o media. Estos medicamentos aumentan los niveles de acetilcolina en el cerebro, un neurotransmisor que ayuda a las células nerviosas a comunicarse entre sí. Según los canales de distribución, el mercado se segmenta en farmacias hospitalarias, farmacias minoristas y farmacias en línea. En 2022, el segmento de farmacias hospitalarias tenía la mayor cuota de mercado de medicamentos para el Alzheimer. Se prevé que el segmento de farmacias en línea registre la CAGR más alta durante 2022-2030.
Mercado de medicamentos para el Alzheimer, por canal de distribución: 2022 y 2030
Análisis regional:
El alcance del informe del mercado de medicamentos para el Alzheimer incluye América del Norte, Europa, Asia Pacífico, América del Sur y Central, y Oriente Medio y África. En 2022, América del Norte ocupó la mayor participación del mercado global debido a las extensas actividades de investigación y desarrollo de las compañías farmacéuticas, y a la prevalencia de la EA y la demencia asociada en la población que envejece en la región. Según la Asociación de Alzheimer, en 2023, más de 6 millones de personas en Estados Unidos fueron diagnosticadas con EA, y ~1 de cada 9 personas de 65 años o más (lo que representa el 10,7 % de la población estadounidense) se vio afectada por la enfermedad de Alzheimer. Además, según las estadísticas proporcionadas por los Centros para el Control y la Prevención de Enfermedades (CDC) en octubre de 2020, la EA es la sexta causa principal de muerte entre los adultos estadounidenses. Además, el creciente gasto en servicios de salud en los EE. UU. impulsa la demanda de medicamentos para el tratamiento de la EA, lo que favorece el crecimiento del mercado de medicamentos para el Alzheimer en la región.
Desarrollos de la industria y oportunidades futuras:
El pronóstico del mercado de medicamentos para el Alzheimer puede ayudar a las partes interesadas en este mercado planifica sus estrategias de crecimiento. A continuación se enumeran algunas iniciativas adoptadas por actores clave que operan en el mercado mundial de medicamentos contra el Alzheimer:
En enero de 2024, Eisai Co., Ltd. y Biogen Inc. anunciaron que la distribución de su desarrollo colaborativo, LEQEMBI, ha sido aprobada en Porcelana. Es un anticuerpo monoclonal humanizado y antisoluble agregado beta amiloide (Aβ) desarrollado para el tratamiento del deterioro cognitivo leve (DCL) debido a la EA y la demencia leve por EA. En mayo de 2023, Otsuka Pharmaceutical, Co. Ltd. y Lundbeck LLC anunció que su desarrollo colaborativo, la Solicitud de Nuevo Fármaco suplementario (sNDA) de REXULTI que contiene brexpiprazol, recibió la aprobación de la Administración de Medicamentos y Alimentos de EE. UU. (FDA) para el tratamiento de síntomas neuropsiquiátricos en la enfermedad de Alzheimer y la demencia. En mayo de 2023, Eli Lilly and Company anunció la resultado positivo para el estudio TRAILBLAZER-ALZ 2 Fase 3 de su fármaco contra el Alzheimer, Donanemab. Según el estudio, Donanemab ralentizó significativamente el deterioro cognitivo y funcional en personas con EA sintomática temprana. En septiembre de 2022, Corium, Inc. lanzó ADLARITY, un sistema transdérmico de donepezilo en EE. UU. Es un medicamento recetado destinado a tratar la demencia leve, moderada o grave en pacientes con EA. Este sistema transdérmico es el primer y único parche de aplicación semanal que administra dosis constantes de donepezilo a través de la piel y no tiene efectos secundarios gastrointestinales. Panorama competitivo y empresas clave:
Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; y Takeda Pharmaceutical Company Limited se encuentran entre los actores destacados perfilados en el informe del mercado de medicamentos para el Alzheimer. Además, durante el estudio se han estudiado y analizado varios otros actores para obtener una visión holística del mercado y su ecosistema.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Alzheimer’s drugs market was valued at US$ 6.21 billion in 2022.
The Alzheimer’s drugs market is expected to be valued at US$ 22.01 billion in 2030.
Alzheimer's disease (AD) is a neurological disorder caused by the progressive death of neurons. The symptoms begin gradually and can lead to dementia. Although the condition cannot be cured completely, there are medicines available that can temporarily alleviate the symptoms and slow down the progression of the disease. Drugs from the class of cholinesterase inhibitors, NMDA receptor antagonists, and combination of these two are indicated for AD.
The Alzheimer’s drugs market, by drug class, is segmented into cholinesterase inhibitors, NMDA receptor antagonists, combination drugs, and pipeline drugs. The cholinesterase inhibitors segment held a larger market share in 2022. The pipeline drugs segment is anticipated to register a higher CAGR during 2022-2030.
The Alzheimer’s drugs market majorly consists of the players such as Pfizer Inc.; Siemens Healthcare GmbH; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Sanofi; Novartis AG; AstraZeneca; AbbVie Inc.; Eisai Co., Ltd.; and Takeda Pharmaceutical Company Limited.
Key factors driving the Alzheimer’s drugs market growth include the high prevalence of AD, particularly in the senior population, and growing research and development activities in the pharmaceutical industry to introduce diagnostics and therapies for the condition.
The List of Companies - Alzheimer’s Drugs Market
- Pfizer Inc.
- Siemens Healthcare GmbH
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Sanofi
- Novartis AG
- AstraZeneca
- AbbVie Inc.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Feb 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Feb 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Feb 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Feb 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Feb 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Feb 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)